Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Link to relevant study record(s)

Description of key information

There were no studies available in which the toxicokinetic properties of the test substance were investigated. However, as per REACH guidance document R7. C (ECHA, 2017), information on absorption, distribution, metabolism and excretion may be deduced from the physicochemical properties. Based on the physicochemical properties, QSAR predictions/modelling as well as the available toxicological data, the test substance is expected to have relatively higher absorption potential via the oral and inhalation route compared to the dermal route. It is likely to be metabolised via aliphatic hydroxylation phase-I reaction. Overall, the substance is expected to have low bioaccumulation potential.

Key value for chemical safety assessment

Bioaccumulation potential:
low bioaccumulation potential
Absorption rate - oral (%):
Absorption rate - dermal (%):
Absorption rate - inhalation (%):

Additional information


Oral absorption

Based on physicochemical properties:

According to REACH guidance document R7.C (ECHA, 2017), oral absorption is maximal for substances with molecular weight below 500. Water-soluble substances will readily dissolve into the gastrointestinal fluids; however, absorption of hydrophilic substances via passive diffusion may be limited by the rate at which the substance partitions out of the gastrointestinal fluid. Further, absorption by passive diffusion is higher at moderate log Kow vales (between -1 and 4). If signs of systemic toxicity are seen after oral administration (other than those indicative of discomfort or lack of palatability of the test substance), then absorption has occurred.

The test substance is a UVCB with mono- and di- phosphate ester constituents of varying carbon chain length (C16-20), having a molecular weight (MW) ranging from 275.18 to 869.51 g/mol and an average MW of 492.3 g/mol.

It is a liquid with poor water solubility of 0.008-0.032 mg/L and a calculated log Kow of >8.53 (based on solubility in octanol and water).

Based on the R7.C indicative criteria, oral uptake of the constituents of the test substance is assessed to be low, given the average molecular weight exceeding 500, poor water solubility and high log Kow values of the test substance. This is supported by the absence of systemic effects in a combined oral repeated dose and reproductive and development toxicity screening study in rats up to the highest tested dose.

Based on QSAR prediction:

Human intestinal absorption (HIA) can also be predicted for the constituents of the test substance using the Multicase model v.3.45 of the OECD QSAR Toolbox v.3.4. HIA is expressed as a percentage of the oral dose absorbed from the gastrointestinal tract. Substances with HIA values of 80% are considered well absorbed and with 90% values are extensively and almost completely absorbed. For those compounds for which the absorption was reported as being poor, the value is 5%.

The estimated HIA of the constituents were found to range from 67.8 to 92.6%, with a weighted average value of 74%. Based on the above data, the test substance is expected to be moderately absorbed through the oral route.

Conclusion:Based on all the available weight of evidence information, the test substance can be expected to have low to moderate absorption through the oral route. Therefore, as a conservative approach, a default value of 50% has been considered for the risk assessment.

Dermal absorption

Based on physicochemical properties:

According to REACH guidance document R7.C (ECHA, 2017), dermal absorption is maximal for substances having molecular weight below 100 together with log Kow values ranging between 2 and 3 and a water solubility in the range of 100-10,000 mg/L. Substances with MW above 500 are considered to be too large to penetrate skin. Further, dermal uptake is likely to be low for substances with log P values <0 or <-1, as they are not likely to be sufficiently lipophilic to cross the stratum corneum. Similarly, substances with water solubility below 1 mg/L are also likely to have low dermal uptake, as the substances must be sufficiently soluble in water to partition from the stratum corneum into the epidermis.

The test substance is a liquid, with an average MW weight of 492.3 g/mol, poor water solubility and an experimental log Kow greater than 4. This suggests that, the test substance will have a low penetration potential through the skin.

Based on QSAR prediction:

The two well-known parameters often used to characterise percutaneous penetration potential of substances are the dermal permeability coefficient (Kp[1]) and maximum flux (Jmax). Kp reflects the speed with which a chemical penetrates across stratum corneum (SC) and Jmax represents the rate of penetration at steady state of an amount of permeant after application over a given area of SC. Out of the two, although Kp is more widely used in percutaneous absorption studies as a measure of solute penetration into the skin. However, it is an impractical parameter because for a given solute, the value of Kp depends on the vehicle used to deliver the solute. Hence, Jmax i.e., the flux attained at the solubility of the solute in the vehicle is considered as the more useful parameter to assess dermal penetration potential as it is vehicle independent (Robert and Walters, 2007).

In absence of experimental data, Jmax can be calculated by multiplying the estimated water solubility with the Kp values from DERMWIN v2.01 application of EPISuite v4.1. The calculated Jmax of the constituents was found to range from 1.33E-03 μg/cm2/h to 8.62E-10 μg/cm2/h, with a weighted average value of 0.01μg/cm2/h.

As per Shenet al. 2014[2], the default dermal absorption for substances with Jmax is ≤0.1 μg/cm2/h is less than 10%. Based on these calculations, the test substance is predicted to be poorly absorbed via the dermal exposure route. 

Conclusion: Based on all the available weight of evidence information, the test substance can be expected to have a very low absorption through the dermal route. However, the test substance is a skin sensitizer which suggests some amount of dermal absorption. Therefore, a value of 10% has been considered for the risk assessment.

Inhalation absorption

Based on physicochemical properties:

According to REACH guidance document R7.C (ECHA, 2017), inhalation absorption is maximal for substances with VP >25 KPa, particle size (<100 μm), low water solubility and moderate log Kow values (between -1 and 4). Very hydrophilic substances may be retained within the mucus and not available for absorption.

The test substance, because of its relatively low vapour pressure of ≤14 Pa 20°C or ≤120 Pa at 50°C (as worst case), will not be available as vapours for inhalation under ambient conditions. Therefore, the substance will neither be available for inhalation as vapours nor as aerosols. Further, if at all there is any inhalation exposure, considering the poor water solubility of the substance it is not expected to be retained in the mucus and the majority of the test substance may reach the lower respiratory tract. The absorption fate of the deposited material thereafter is expected to be similar to the oral route/gastrointestinal tract.

Conclusion:Overall if inhaled, based on all the available weight of evidence information, the test substance can be expected to have moderate absorption through the inhalation route. Therefore, as a conservative approach, a default value of 100% has been considered for the risk assessment.


Based on identified literature:

In vivometabolic transformation study following oral or intraperitoneal administration of 14C-labelled shorter chain trialkyl phosphate ester, tributyl phosphate (TBP), revealed oxidation as the first stage metabolic process, catalysed by cytochrome P-450-dependent mono-oxygenase, at the ω or ω -1 position on the butyl chains. The hydroxyl groups generated at the ω or ω -1 position were further oxidized to produce carboxylic acids and ketones, respectively (Suzukiet al., 1984a). Following these oxidations, the oxidized alkyl moieties were removed as glutathione conjugates, which were then excreted as N –acetyl cysteine derivatives in urine (Suzukiet al., 1984b).

Based on QSAR modelling:

The above evidence is supported by the predicted metabolism for the test substance using thein vivorat metabolism and the rat liver S9 metabolism simulators of the OECD QSAR Toolbox v.3.4.According to both simulators, all the major constituents (present at >5%) are primarily predicted to undergo aliphatic hydroxylation atωposition, as the first metabolic reaction. See below table for the reaction sites. For further details, refer to the read across justification.


Based on the MW and physicochemical information (log Kow and water solubility) and metabolism prediction, the bioaccumulation potential of the substance is expected to be low.


Based on the MW and poor water solubility, the urinary excretion of the test substance as such is expected to be low. Nevertheless, similar to TBP, there will be urinary excretion of the resultant water soluble metabolites.

[1]Log Kp = -2.80 + 0.66 log kow – 0.0056 MW